BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 16059699)

  • 1. Utilization of the embryonated egg for in vivo evaluation of the anti-influenza virus activity of neuraminidase inhibitors.
    Sauerbrei A; Haertl A; Brandstaedt A; Schmidtke M; Wutzler P
    Med Microbiol Immunol; 2006 Jun; 195(2):65-71. PubMed ID: 16059699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza infection of the embryonated hen's egg/an alternative model for in vivo evaluation of antiviral compounds.
    Härtl A; Sauerbrei A; Stelzner A; Wutzler P
    Arzneimittelforschung; 2004; 54(2):130-4. PubMed ID: 15038464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells.
    Govorkova EA; Fang HB; Tan M; Webster RG
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4855-63. PubMed ID: 15561867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
    Ferraris O; Kessler N; Lina B
    Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antiviral agents for influenza].
    Mitamura K
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():798-803. PubMed ID: 12722319
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
    Gubareva LV; Webster RG; Hayden FG
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
    Mungall BA; Xu X; Klimov A
    Virus Res; 2004 Jul; 103(1-2):195-7. PubMed ID: 15163509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.
    McSharry JJ; McDonough AC; Olson BA; Drusano GL
    Clin Diagn Lab Immunol; 2004 Jan; 11(1):21-8. PubMed ID: 14715540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuraminidase inhibitors in patients with underlying airways disease.
    Williamson JC; Pegram PS
    Am J Respir Med; 2002; 1(2):85-90. PubMed ID: 14720062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia.
    Hurt AC; Barr IG; Durrant CJ; Shaw RP; Sjogren HM; Hampson AW
    Commun Dis Intell Q Rep; 2003; 27(4):542-7. PubMed ID: 15508516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
    Hurt AC; Barr IG; Hartel G; Hampson AW
    Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.
    Molla A; Kati W; Carrick R; Steffy K; Shi Y; Montgomery D; Gusick N; Stoll VS; Stewart KD; Ng TI; Maring C; Kempf DJ; Kohlbrenner W
    J Virol; 2002 Jun; 76(11):5380-6. PubMed ID: 11991966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
    Govorkova EA; Leneva IA; Goloubeva OG; Bush K; Webster RG
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2723-32. PubMed ID: 11557461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuraminidase inhibitors for treatment of influenza A and B infections.
    MMWR Recomm Rep; 1999 Dec; 48(RR-14):1-9. PubMed ID: 10632443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
    Bantia S; Parker CD; Ananth SL; Horn LL; Andries K; Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin T; Hutchison TL; Montgomery JA; Kellog DL; Babu YS
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1162-7. PubMed ID: 11257030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influenza virus neuraminidase inhibitors.
    Gubareva LV; Kaiser L; Hayden FG
    Lancet; 2000 Mar; 355(9206):827-35. PubMed ID: 10711940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus.
    Abed Y; Goyette N; Boivin G
    Antivir Ther; 2004 Aug; 9(4):577-81. PubMed ID: 15456089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neuraminidase inhibitor, anti-influenzal agent--mechanism of action, and how to use clinically].
    Kaji M
    Nihon Rinsho; 2003 Nov; 61(11):1975-9. PubMed ID: 14619441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuraminidase inhibitors for preventing and treating influenza in children.
    Matheson NJ; Symmonds-Abrahams M; Sheikh A; Shepperd S; Harnden A
    Cochrane Database Syst Rev; 2003; (3):CD002744. PubMed ID: 12917931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay.
    Gubareva LV; Webster RG; Hayden FG
    Antiviral Res; 2002 Jan; 53(1):47-61. PubMed ID: 11684315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.